Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06586593 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)

Study acronym: NEOMEL
StatusUnknown
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 19, 2024 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Eligibility criteria revised
    • Secondary endpoints revised (7)
    • Site contacts updated at 1 of 9 sites
    • Study title revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to evaluate efficacy and tolerance of real life neoadjuvant immunotherapy in advanced yet operable melanoma. The complete histological response will be assessed.
Trial Details
NCT Number NCT06586593
Lead Sponsor Centre Hospitalier Universitaire de Besancon
Conditions
(from sponsor)		 Melanoma Metastatic
Enrollment 77 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov